A Highly Selective JAK inhibitor SHR0302 for the Treatment of Patients with Moderate to Severe Atopic Dermatitis: A Successful Phase II Study

Time: 12:00 pm
day: Day 2 AM - Track 2

Details:

• Showcasing phase II study results
• Learnings from conducting dermatological trial in China
• Sharing experience on conducting big indication clinical study for a startup biotech

Speakers: